Europe
Santhera said the restructuring will allow the company to focus on the development of vamorolone, a first-in-class dissociative steroid with a novel mode of action that it gained the rights to from ReveraGen BioPharma.
Kiadis has three compounds in the clinic: K-NK002 in Phase II for HSCT in blood cancer; K-NK003 for relapsed or refractory acute myeloid leukemia (AML); K-NK-ID101 for COVID-19.
A seroprevalance study of 15,591 children in Bavaria, published October 28th in Med, revealed a six-fold greater prevalence of the SARS-CoV-2 virus than reported cases.
Novo Nordisk announced today that it has ended its development of the anti-IL-21 antibody NN9828 in combination with Victoza. The decision was made after analyzing Phase II clinical trial data in patients with Type 1 diabetes.
AstraZeneca is divesting two cardiovascular drugs to Germany’s Cheplapharm Arzneimittel GmbH for $400 million, which will allow the UK pharma giant to reinvest in its main therapy areas.
It was a particularly busy week for announcements about clinical trials, both related to COVID-19 and everything else. Here’s a look.
AbCellera and Kodiak Sciences have announced a new partnership to create and develop therapeutic antibodies for ophthalmologic indications. The two companies originally entered a partnership in August 2016.
BioSpace provides an up-to-date overview of these deals and the projected COVID-19 vaccine doses each company plans to have within the next couple of years.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
AstraZeneca and Daiichi Sankyo’s Enhertu received supplemental Biologics License Application acceptance and U.S. priority review for the treatment of HER2-positive metastatic gastric – or gastroesophageal junction cancer.
PRESS RELEASES